The Global Regenerative Medicine Market Size is valued at 30.50 billion in 2023 and is predicted to reach 93.29 billion by the year 2031 at a 15.14% CAGR during the forecast period for 2024-2031.
The preference for individualized therapeutic approaches over conventional treatment modalities has changed due to several developments in biological therapy. For those in the market working on creating natural treatments, this has opened up a lot of prospects. Numerous developments in biological therapeutics have shifted the preference towards personalized medicinal strategies over traditional treatment methods, resulting in the Regenerative Medicine market expansion.
The COVID-19 pandemic has significantly influenced several businesses, notably the T-cell therapies and regenerative medicine industry. The SARS-CoV-2 coronavirus outbreak has dramatically impacted the delivery of CAR T-cell therapy. This effect has spread beyond patient care to include administration, logistics, and the scarcity of healthcare resources. Clinical trial enrolment and other research activity have slowed down at some universities. Yet, as market participants like Novartis continue to open up access to treatments like MultiStem, a very relevant COVID-19 medication from Athersys, Inc., the market continues to grow.
Recent Developments:
- In April 2022, Obecabatagene autoleucel, a CD19-directed autologous chimeric antigen receptor T therapy being investigated in the ongoing FELIX Phase 2 study of leukaemia, has been given the Regenerative Medicine Advanced Therapy designation by the U.S. Food and Drug Administration (FDA). This was announced by Autolus Therapeutics plc.
Competitive Landscape:
Some of the Regenerative Medicine market players are:
- AstraZeneca plc;
- Hoffmann-La Roche Ltd.;
- Integra Lifesciences Corp.;
- Astellas Pharma, Inc.;
- Cook Biotech, Inc.;
- Bayer AG;
- Pfizer, Inc.;
- Merck KGaA;
- Abbott;
- Vericel Corp.;
- Novartis AG;
- GlaxoSmithKline (GSK);
- Baxter International, Inc.;
- Boehringer Ingelheim;
- Amgen, Inc.;
- Cesca Therapeutics, Inc.;
- S. Stem Cell, Inc.;
- Bristol-Myers Squibb;
- Eli Lilly and Company;
- NuVasive, Inc.;
- Organogenesis, Inc.;
- MiMedx Group, Inc.;
- Takara Bio, Inc.;
- Osiris Therapeutics, Inc.;
- Corline Biomedical AB
Market Segmentation:
The Regenerative Medicine market is segmented based on product and therapeutic category. Based on product, the market is segmented as Therapeutics, Primary cell-based therapeutics, Stem Cell & Progenitor Cell-based therapeutics. By therapeutics category, the market is segmented into Dermatology, Musculoskeletal, Immunology & Inflammation, and Oncology.
Based On Product, The Therapeutics Segment Significantly Contributes To The Regenerative Medicine Market
Due to the growing elderly population and more excellent incidence rates of age-related and degenerative illnesses, the therapeutics category held the most significant revenue share of the regenerative medicine market. Researchers have been inspired to create alternative solutions by the rising prevalence of diseases for which there are no effective treatments, including cancer, diabetes, and neurodegenerative illnesses like AMD. For instance, Kite, a Gilead Company, declared in April 2022 that the U.S. FDA had approved Yescarta, a CAR T-cell therapy product, for treating refractory or relapsed large B-cell lymphoma.
The Oncology Segment Witnessed Growth At A Rapid Rate
Due to the rising incidence of cancer worldwide, the oncology segment led the market for regenerative medicine. Numerous governmental agencies and private businesses have invested much in cancer research and the creation of cutting-edge cell therapies. A partnership agreement between Calidi Biotherapeutics (CBT) and First Light Acquisition Group (FLAG) was signed in January 2023 with the intention of using stem cell-based platforms to revolutionize oncolytic virotherapies.
The North America Regenerative Medicines Market Holds A Significant Revenue Share In The Region
North America controlled the market for regenerative medicine. The significant regenerative medicine market growth is attributable to the availability of public and private development financing, the existence of cutting-edge technological frameworks to assist the quick detection of chronic diseases, and the high healthcare spending in the area. In addition, the region has grown as a result of numerous ongoing clinical trials for regenerative medicine by important industry players. To prevent acute graft versus host disease in adults and paediatric patients two years of age and older undergoing hematopoietic stem cell transplantation, Bristol Myers Squibb acquired U.S. FDA approval for Orencia in December 2021. (HSCT).
Regenerative Medicine Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 30.50 Bn |
|
Revenue forecast in 2031 |
USD 93.29 Bn |
|
Growth rate CAGR |
CAGR of 15.14% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million, and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product And Therapeutic Category |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
AstraZeneca plc; F. Hoffmann-La Roche Ltd.; Integra Lifesciences Corp.; Astellas Pharma, Inc.; Cook Biotech, Inc.; Bayer AG; Pfizer, Inc.; Merck KGaA; Abbott; Vericel Corp.; Novartis AG; GlaxoSmithKline (GSK); Baxter International, Inc.; Boehringer Ingelheim; Amgen, Inc.; Cesca Therapeutics, Inc.; U.S. Stem Cell, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; NuVasive, Inc.; Organogenesis, Inc.; MiMedx Group, Inc.; Takara Bio, Inc.; Osiris Therapeutics, Inc.; Corline Biomedical AB. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
